Treatment of rhabdomyosarcoma and lung adenocarcinoma cells with the a JMJD-antagonist, JIB-04 [225], inhibited tumor cell growth, decreased Hh-target gene expression, and induced GLI1 degradation [204]. This evidence concerns the gene GLI1 and rhabdomyosarcoma.